Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus CAMBIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus CAMBIA.
ANAPROX DS vs CAMBIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating inflammation, pain, and fever.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
50 mg orally once daily as needed for acute migraine, maximum 1 packet (50 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life of diclofenac (active moiety) is approximately 1.9-2.1 hours. The clinical context: short half-life supports twice-daily dosing for acute pain.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Approximately 50% of a dose is excreted in urine primarily as metabolites and conjugates, with less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 40%.
Category C
Category C
NSAID
NSAID